



South Jersey's center for biomedical research

Classes in the MSMPI Program are offered on both the Genesis Biotechnology Group campus in Hamilton and the RowanGSBS campus in Stratford, which are approximately 37 miles apart and easily accessible by personal car.

All accepted students begin in the fall semester.

Application deadline is July 15th.

Our Graduates

Within a year of graduating, 94% of MSMPI graduates have found positions in their field. They have gone on to continue their education in advanced degree programs or have accepted positions as scientists, research assistants, laboratory technicians and managers, or senior scientific strategists at such organizations as:

- Bristol-Myers Squibb**
- Covance**
- Incyte Corporation**
- Kansas University Medical Center**
- L'Oréal Group**
- Merck Pharmaceuticals**
- Novartis**
- Wake Forest University**
- WuXi AppTec**

A large yellow map of New Jersey is the central focus. At the top, there are three overlapping speech bubbles in blue, yellow, and red, containing icons for a pill, a molecular structure, a lightbulb, and a biohazard symbol. A speech bubble with the text "Let's talk science!" is positioned over the Philadelphia area, labeled "PHILA". The New York City area is labeled "NYC". At the bottom of the map, the text "ROWAN UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES" is displayed. Below the map, contact information is provided: "42 East Laurel Road, Suite 2200 Stratford, NJ 08084", "P: 856-566-6282", "F: 856-566-6232", and "gsbs-stratford@rowan.edu rowan.edu/gsbs".



MOLECULAR PATHOLOGY AND IMMUNOLOGY PROGRAM

MASTER OF SCIENCE (MS)

rowan.edu/gsbs

 **Rowan University**

GRADUATE SCHOOL OF
BIOMEDICAL SCIENCES



About the MSMPI Program

The Master of Science in Molecular Pathology and Immunology (MSMPI) program is a 17-month, interactive learning experience that combines traditional classroom instruction with hands-on experience at the region's largest biotechnology consortium, the Genesis Biotechnology Group (GBG).

You will take courses at both the Rowan GSBS campus in Stratford and at the Hamilton campus of GBG. In addition, you will complete two rotations and a thesis project performing research at your choice of several laboratories at GBG.

As part of your degree, you will have the opportunity to work on real-life science problems, such as finding new ways to diagnose diseases and doing research to find novel treatments for disease. Some of the research areas in which you can specialize are:

- Cancer progression, monitoring and treatment
- Metabolic and cardiac diseases
- Advanced biomarker discovery
- Microbial antibiotic resistance

No other degree program will provide you with the opportunity to gain hands-on research experience at a biotechnology company - experience that gives you an advantage in today's competitive employment environment.

The MSMPI curriculum

- Biochemistry and Molecular Biology
- Cell Biology
- Laboratory Rotations
- Readings in Molecular Pathology and Immunology I and II
- Responsible Conduct in Research
- Research in Molecular Pathology and Immunology I and II
- Seminar in Molecular Pathology and Immunology
- Techniques in Molecular Diagnostics
- Thesis Research / MSMPI
- Topics in Molecular Diagnostics



Laboratories available for rotations and thesis research:

- **The Institute for Biomarker Research** through partnerships with healthcare provider clients, focuses its research on personalized solutions for the prevention, detection, and treatment of chronic diseases.
- **Oncoveda Cancer Research Center** is working on the discovery and of novel small molecule immune-oncology medicines, with a focus on treating urogenital cancers.
- **The Institute for Metabolic Disorders** focuses on the discovery of new therapies to treat fatty liver disease. It is estimated that - 20% of the world's population has fatty liver disease. Presently, there is an unmet medical need for novel treatment modalities, as presently there are no drugs available.
- **Venenum Biodesign, L.L.C.** studies the initial steps of drug invention, then develops and partners new drug candidates to bring them to patients.